When a global leader like AstraZeneca set out to replace its enterprise CRM, failure wasn’t an option. Siebel had reached its limits, it was costly to run, hard to evolve, and misaligned across regions. The company needed a cloud-native path forward, but also a decision process executives could trust: neutral, transparent, and anchored in business value.
Prolifics, partnering with Enable, brought an engineering-first, vendor-agnostic methodology. We interviewed stakeholders across sales, medical, and compliance; translated pain points into weighted requirements; and built a side-by-side vendor demonstration script to ensure apples-to-apples evaluation. Our team modeled 3–5-year ROI/TCO, ran sensitivity analyses, and surfaced risks early with mitigation plans. Executive dashboards and heat maps made the trade-offs unmistakable.
The outcome: AstraZeneca selected Veeva, backed by defensible scoring, proven life-sciences maturity, robust security, and a scalable, cloud-native roadmap. We didn’t stop at the decision. A phased migration and adoption plan, API-first integration strategy, and role-based training blueprint accelerated time-to-value while reducing run costs. This is how high-stakes technology choices should be made: evidence-led, compliant, and future-ready. Read the full case study to see the measurement matrix, ROI model, and roadmap, and discover how Prolifics de-risks complex transformations with speed and certainty. See what confident transformation looks like today.
